within Pharmacolibrary.Drugs.ATC.L;

model L01EA05
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.54,
    Cl             = 0.0005149999999999999,
    adminDuration  = 600,
    adminMass      = 45 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.11,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.006616666666666667,
    Tlag           = 10.200000000000001,            
    Vdp             = 0.576,
    k12             = 64.8,
    k21             = 64.8
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01EA05</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Ponatinib is an oral tyrosine kinase inhibitor approved for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), particularly in cases with resistance or intolerance to prior tyrosine kinase inhibitor therapy, including cases with T315I mutation. It is currently approved and used in clinical practice.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in adult patients with hematologic malignancies (mainly CML and Ph+ ALL), after repeated oral administration of ponatinib at a daily dose of 45 mg. The population was comprised of both male and female subjects.</p><h4>References</h4><ol><li><p>Hanley, MJ, et al., &amp; Venkatakrishnan, K (2022). Population Pharmacokinetics of Ponatinib in Healthy Adult Volunteers and Patients With Hematologic Malignancies and Model-Informed Dose Selection for Pediatric Development. <i>Journal of clinical pharmacology</i> 62(4) 555–567. DOI:<a href=\"https://doi.org/10.1002/jcph.1990\">10.1002/jcph.1990</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34699069/\">https://pubmed.ncbi.nlm.nih.gov/34699069</a></p></li><li><p>Narasimhan, NI, et al., &amp; Sonnichsen, D (2013). Effects of food on the pharmacokinetics of ponatinib in healthy subjects. <i>Journal of clinical pharmacy and therapeutics</i> 38(6) 440–444. DOI:<a href=\"https://doi.org/10.1111/jcpt.12082\">10.1111/jcpt.12082</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/23888935/\">https://pubmed.ncbi.nlm.nih.gov/23888935</a></p></li><li><p>Narasimhan, NI, et al., &amp; Sonnichsen, D (2014). Evaluation of pharmacokinetics and safety of ponatinib in subjects with chronic hepatic impairment and matched healthy subjects. <i>Cancer chemotherapy and pharmacology</i> 74(2) 341–348. DOI:<a href=\"https://doi.org/10.1007/s00280-014-2511-z\">10.1007/s00280-014-2511-z</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/24934866/\">https://pubmed.ncbi.nlm.nih.gov/24934866</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01EA05;
